Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Among these ACPA-positive patients 58% were also positive for anti-cit-enolase, 52% for anti-cit-vim, and 31% for anti-cit-fib (see Table 1).Characteristics at baseline of the rheumatoid arthritis cohortACPA-positiveACPA-negativeACPA-positiveACPA-negativeRF-negativeRF-negativeNumbers125581445Age, years48 (40 to 56)58 (52 to 64)43 (29 to 50)59 (55 to 65)Female sex97 (78 %)35 (60 %)11 (79%)27 (60 %)Ever smoking71 (66 %)36 (67 %)7 (64 %)28 (67 %)HLA-DRB1 SE109 (89 %)34 (60 %)13 (100 %)25 (57 %)PTPN22 risk allele40 (33 %)10 (18 %)5 (38 %)6 (14 %)DAS28-ESR5.6 (5.0 to 6.2)5.8 (5.1 to 6.3)6.0 (5.2 to 6.2)5.9 (5.1 to 6.3)ESR28 (16 to 40)23 (12 to 39)28 (25 to 35)21 (12 to 35)HAQ1.1 (0.8 to 1.6)1.3 (0.9 to 1.5)1.0 (0.8 to 1.5)1.3 (0.9 to 1.5)Prednisolone16 (13 %)10 (18 %)1 (7 %)7 (16 %)Calcium and/or vitamin D supplement7 (6 %)3 (5 %)1 (7 %)1 (2 %)Hormone replacement therapy9 (7 %)7 (12 %)0 (0 %)5 (11 %)RF-positive111 (89 %)13 (22 %)Anti-cit-enolase (amino acids 5 to 21)+73 (58 %)0 (0 %)6 (43 %)0 (0 %)Anti-cit-vimentin (amino acids 60 to 75)+65 (52 %)0 (0 %)7 (50 %)0 (0 %)Anti-cit-fibrinogen (amino acids 563 to 583)+39 (31 %)1 (2 %)2 (14 %)1 (2 %)Values are given as number (%) or median (25 to 75% interquartile range: (IQR))Number of missing observations for smoking habits, HLA-DRB1 SE, PTPN22, use of calcium and/or vitamin D, use of hormone replacement therapy, use of prednisolone and HAQ, were 22, 3, 5, 2, 2, 5 and 4 respectively ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate (mmHg/hour), HAQ health assessment questionnaire (range: 0 to 3), cit citrullinated, + positive
Source: Increased RANKL levels in ACPA-positive untreated early RA. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Seven patients were excluded from posttreatment analyses due to delayed MTX treatment initiation (>7 weeks after baseline) or secession of treatment; these patients were, however, included in pretreatment (baseline) analyses.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Serum RANKL levels associate with anti: citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate
Study design awaiting verification · Arthritis Research & Therapy · 2015
Original publication title
Serum RANKL levels associate with anti: citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate
© Hensvold et al. 2015
Original publication · Publisher record [link unavailable; original address: https://doi.org/10.1186/s13075-015-0760-9] · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Receptor activator of nuclear factor kappa B ligand (RANKL) is a key regulator of bone metabolism. Anti-citrullinated protein antibodies (ACPA) have been suggested to cause bone destruction by osteoclast activation. We investigated the relationship between RANKL and ACPA in patients with early untreated rheumatoid arthritis (RA).
Source: IntroductionAbstract: What methods does the paper describe?
Patients with newly diagnosed untreated RA (n = 183) were analyzed at baseline and 3 months after initiating methotrexate (MTX) treatment. Serum RANKL (total RANKL), ACPA (anti-CCP2) and ACPA specificities (anti-citrullinated (cit)-vimentin, anti-cit-enolase and anti-cit-fibrinogen) were determined by enzyme-linked immunosorbent assay (ELISA). Synovial RANKL expression was evaluated by immunohistochemistry in a small group of patients (n = 15). The relationship between anti-cit-vim antibodies and bone destruction was further validated in 1116 RA patients included in the EIRA cohort. Pearson’s chi-square test, Wilcoxon rank sum test, Wilcoxon signed rank test and linear regression models were used.
Source: MethodsAbstract: Results
Serum RANKL concentration was significantly higher (p <0.05) in ACPA-positive (median: 689 pmol/L, IQR 342 to 1253) compared with ACPA-negative (median: 159 pmol/L, IQR 96 to 243) patients and this difference was also seen for synovial RANKL expression. Serum RANKL associated with ACPA (p <0.05) and bone erosions in rheumatoid factor (RF)-negative patients (n = 59). Among ACPA specificites, anti-cit-vimentin (amino acids 60 to 75) was associated with higher RANKL concentration and higher prevalence of bone erosion (p <0.05). Significant reductions in both serum RANKL and ACPA levels were observed after 3 months of MTX treatment (p <0.05).
Source: ResultsAbstract: Conclusions
RANKL was elevated in ACPA-positive and in anti-cit-vimentin-positive patients with early untreated RA and associated with bone erosions. These findings give further support for an early direct pathogenic link between ACPA and bone destruction in RA.
Source: ConclusionsAuthors’ abstract
Introduction
Receptor activator of nuclear factor kappa B ligand (RANKL) is a key regulator of bone metabolism. Anti-citrullinated protein antibodies (ACPA) have been suggested to cause bone destruction by osteoclast activation. We investigated the relationship between RANKL and ACPA in patients with early untreated rheumatoid arthritis (RA).
Methods
Patients with newly diagnosed untreated RA (n = 183) were analyzed at baseline and 3 months after initiating methotrexate (MTX) treatment. Serum RANKL (total RANKL), ACPA (anti-CCP2) and ACPA specificities (anti-citrullinated (cit)-vimentin, anti-cit-enolase and anti-cit-fibrinogen) were determined by enzyme-linked immunosorbent assay (ELISA). Synovial RANKL expression was evaluated by immunohistochemistry in a small group of patients (n = 15). The relationship between anti-cit-vim antibodies and bone destruction was further validated in 1116 RA patients included in the EIRA cohort. Pearson’s chi-square test, Wilcoxon rank sum test, Wilcoxon signed rank test and linear regression models were used.
Results
Serum RANKL concentration was significantly higher (p <0.05) in ACPA-positive (median: 689 pmol/L, IQR 342 to 1253) compared with ACPA-negative (median: 159 pmol/L, IQR 96 to 243) patients and this difference was also seen for synovial RANKL expression. Serum RANKL associated with ACPA (p <0.05) and bone erosions in rheumatoid factor (RF)-negative patients (n = 59). Among ACPA specificites, anti-cit-vimentin (amino acids 60 to 75) was associated with higher RANKL concentration and higher prevalence of bone erosion (p <0.05). Significant reductions in both serum RANKL and ACPA levels were observed after 3 months of MTX treatment (p <0.05).
Conclusions
RANKL was elevated in ACPA-positive and in anti-cit-vimentin-positive patients with early untreated RA and associated with bone erosions. These findings give further support for an early direct pathogenic link between ACPA and bone destruction in RA.
Publication and source details
Original title: Serum RANKL levels associate with anti: citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate
Aase Haj Hensvold; Vijay Joshua; Wanying Li; Michaela Larkin; Ferhan Qureshi; Lena Israelsson; Leonid Padyukov; Karin Lundberg; Nadine Defranoux; Saedis Saevarsdottir; Anca Irinel Catrina
Arthritis Research & Therapy · 2015
© Hensvold et al. 2015https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T20:22:05.589987+00:00
DOI: 10.1186/s13075-015-0760-9 · PMC4559929